DRG Market Assessment reports

Treatment of CSU and CIndU is dominated by oral medications, including approved therapies such as first- and second-generation antihistamines and a range of off-label options (e.g.,…

Immune thrombocytopenic purpura (ITP) is an autoimmune disorder marked by increased platelet destruction and impaired megakaryocyte production. Bleeding ranges from petechiae to lifethreatening…

Rheumatoid arthritis (RA) patients who are refractory to one or more tumor necrosis factor (TNF)-alpha inhibitors are generally prescribed a non-TNF-targeted therapy (e.g., Bristol Myers Squibb’s…

Neuromyelitis optica spectrum disorder (NMOSD) is a rare, chronic autoimmune neuroinflammatory disorder marked by optic neuritis and longitudinally extensive transverse myelitis, often leading to…

The treatment landscape for advanced platinumresistant ovarian cancer remains highly challenging, as conventional singleagent chemotherapies provide limited and shortlived benefit. Unlike the…

Multiple myeloma represents a complex and increasingly competitive hematologic malignancy landscape, with treatment approaches evolving rapidly across lines of therapy. While IMiDs, proteasome…

Epilepsy is a complex neurological disorder marked by recurrent seizures, affecting approximately 4.7 million people across the major markets, as reported by Clarivate Epidemiology. Given epilepsy…

The introduction of the immune checkpoint inhibitors Keytruda (Merck & Co.), Opdivo ± Yervoy, and Opdualag (Bristol Myers Squibb), as well as BRAF/MEK inhibitor combinations such as Roche /…

Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…

Immune checkpoint inhibitors such as Opdivo (Bristol Myers Squibb / Ono Pharmaceutical) and Keytruda (Merck & Co.) have transformed gastroesophageal cancer treatment, driving significant market…

The treatment of multiple myeloma is becoming increasingly complex. Sanofi’s Sarclisa received a label expansion for the first-line treatment of autologous stem-cell transplantation-ineligible…

Dravet syndrome (DS) is a rare, severe, pediatric-onset genetic epileptic encephalopathy that typically emerges within the first year of life and is marked by developmental delays and multiple…